Vimarsana
Biggest News Aggregation in the World

Page 50 - Aet News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aet. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aet Today - Breaking & Trending Today

Profitability Is King in 2024's Fundraising Environment, Expert Says - Vimarsana News

Profitability Is King in 2024's Fundraising Environment, Expert Says

This year's digital health fundraising environment requires startups to focus more on their unit economics and pathway to profitability, according to Ian Wijaya, managing director at Lazard. He predicted that the ability to achieve profitability will be much more important in 2024 than it has been in the past four years or so.

Disruption from Weight Loss Drugs Has Only Scratched the Surface. Telehealth Can Help Overcome the Next Big Obstacle - Vimarsana News

Disruption from Weight Loss Drugs Has Only Scratched the Surface. Telehealth Can Help Overcome the Next Big Obstacle

Telehealth is poised to serve as an essential tool to fill an exploding demand for care. Providers and digital health companies need to act now by expanding telehealth offerings that include on-demand care teams knowledgeable and experienced in GLP-1 drugs, but also overall health and wellness strategies.

10 Key MedTech Themes for 2024 - Vimarsana News

10 Key MedTech Themes for 2024

Increasing innovation in, and consumer demand for, healthcare technology continue to transform the Medtech industry, including in digital health, wearables, diagnostics, telemedicine and other health IT solutions.

Bayer's Cost-Cutting Plans Take Aim at Multiple Layers of Management - Vimarsana News

Bayer's Cost-Cutting Plans Take Aim at Multiple Layers of Management

CEO Bill Anderson said despite prior cost-cutting measures, Bayer still has too many layers of management and bureaucracy. A new restructuring will come with layoffs but the corporate shakeup plan does not yet include a separation of Bayer’s business units.

Vertex's CRISPR Gene Therapy Lands Another FDA Nod in a Rare Blood Disease - Vimarsana News

Vertex's CRISPR Gene Therapy Lands Another FDA Nod in a Rare Blood Disease

The FDA approved Vertex Pharmaceuticals’ gene therapy Casgevy for treating beta thalassemia, an inherited blood disease that leads to low levels of functioning hemoglobin. Last month, the one-time treatment won its first FDA nod for treating sickle cell disease.